Form 4: OrbiMed Advisors Sells 230,321 Shares of Passage Bio, Inc.

OrbiMed Advisors LLC, a significant shareholder of Passage Bio, Inc., sold 230,321 shares of common stock at a price of $0.60 per share on December 20, 2024.

Summary

• OrbiMed Advisors LLC, along with OrbiMed Capital GP VII LLC, reported a sale of 230,321 shares of Passage Bio, Inc. common stock.
• The transaction occurred on December 20, 2024, at a price of $0.60 per share.
• Following the transaction, OrbiMed Advisors indirectly beneficially owns 7,404,869 shares of Passage Bio, Inc.
• The shares are held of record by OrbiMed Private Investments VII, LP (OPI VII).
• OrbiMed Capital GP VII LLC is the general partner of OPI VII, and OrbiMed Advisors LLC is the managing member of GP VII.
• Both OrbiMed Advisors and GP VII disclaim beneficial ownership of the securities except to the extent of their pecuniary interest.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it is a standard transaction disclosure. The sale could be interpreted negatively, but it's not inherently positive or negative.

Negatives

• OrbiMed Advisors, a significant shareholder, has reduced its position in Passage Bio, Inc. by selling 230,321 shares.

Risks

• The sale by a major shareholder like OrbiMed Advisors could potentially signal a lack of confidence in the company's future prospects.
• The market may interpret this sale as a negative indicator, potentially impacting the stock price.

Management Comments

• Carl L. Gordon, Member of OrbiMed Advisors LLC, and OrbiMed Capital GP VII LLC, signed the report.
• OrbiMed Advisors and GP VII disclaim beneficial ownership of the securities except to the extent of their pecuniary interest.

Industry Context

This transaction is a routine disclosure of share sales by a major shareholder and is common in the biotech industry where investment firms often adjust their positions.

Comparison to Industry Standards

• Share sales by institutional investors are a normal part of market activity, especially in the biotech sector where investment portfolios are actively managed.
• Similar transactions are regularly reported by other investment firms like Baker Bros. Advisors or RA Capital Management, who also hold significant positions in various biotech companies.
• The size of the sale, 230,321 shares, is not unusual for a fund of OrbiMed's size, and the price of $0.60 per share is reflective of the current market valuation of Passage Bio.

Stakeholder Impact

• The sale may cause a slight negative reaction from shareholders due to the reduction in a major shareholder's position.
• The impact on employees, customers, suppliers, and creditors is likely to be minimal.

Key Dates

Keywords

OrbiMed Advisors, Passage Bio, Share Sale, Beneficial Ownership, SEC Form 4, Stock Transaction